property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HIV AIDS CTU Review Meeting SEP 1.

Date: May 18, 2020.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G21, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Robert C. Unfer, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G21, Rockville, MD 20892–9823, 240–669–5035, unferr@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)


Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–09197 Filed 4–29–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) hereby announces updates to the Best Pharmaceuticals for Children Act (BPCA) Program priorities for 2020–2021. The Best Pharmaceuticals for Children Act (BPCA) Program seeks to improve the level of information on the safe and effective use of pharmaceuticals used to treat children. The BPCA requires that the NIH identify the drugs of highest priority for study in pediatric populations, publish a list of drugs/needs in pediatric therapeutics, and fund studies in the prioritized areas. This notice will provide a brief update on the current progress of the BPCA Program and provide the current Priority List of Needs in Pediatric Therapeutics.

DATES: The next BPCA stakeholders meeting will take place on December 14–15, 2020. More information will be provided on the BPCA website as it becomes available.

ADDRESSES: The complete Priority List of Needs in Pediatric Therapeutics 2020–2021 can be found on the BPCA website at the following address: https://www.nichd.nih.gov/research/support/b pca/activities.

FOR FURTHER INFORMATION CONTACT: Dr. Perdita Taylor-Zapata via email at taylorpe@mail.nih.gov; or by phone at 301–496–9584.

SUPPLEMENTARY INFORMATION: The BPCA requires that the NIH, in consultation with the Food and Drug Administration and experts in pediatric research, identify the drugs and therapeutic areas of highest priority for study in pediatric populations. The NIH BPCA Program has been in existence since 2004 and is overseen by the Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB) of the NICHD. To date, the BPCA Program has prioritized over one-hundred and fifty (150) drugs and therapeutic areas, funded more than forty (40) clinical studies, and improved the labeling to date of eleven (11) drugs and two (2) devices in the ongoing effort of advancing the knowledge of dosing, safety and effectiveness of medicines used in children. However, despite these and many other efforts, many gaps in knowledge still remain regarding the use of therapeutics in children including the correct dosage, appropriate indications, side effects, and safety concerns in the short- and long-term. These gaps result in inadequate labeling and/or wide-spread off-label use of prescription drugs in children. Off-label use of a drug substantially limits the ability to obtain important clinical information for more generalized use of a drug product, such as characterizing changes in drug metabolic pathways and response during growth and development, identifying precision-based treatments (i.e., impact of genotype and phenotype of medication responses), and determining short- and long-term effects of medications. The mandate of the NIH BPCA Program is to identify knowledge gaps that exist in pediatric therapeutics and to promote an increase in evidence-based data about medications used in children. Please see the BPCA website for more information: https://www.nichd.nih.gov/research/support/b pca/about.

Update on BPCA Prioritization

The BPCA Priority List consists of key therapeutic needs in the medical treatment of children and adolescents identified for further study; it is organized by therapeutic area, which can be a group of conditions, a subgroup of the population, or a setting of care. The first priority list of off-patent drugs needing further study under the 2002 BPCA legislation Public Law 107–109, was published in January 2003 in the Federal Register (FR Vol. 68, No. 13; Tuesday, January 21, 2003: 2789–2790). The most recent priority list has been published to the BPCA website; more information on the prioritization process, all BPCA priority lists, and all Federal Register Notices can be found on the BPCA website: https://www.nichd.nih.gov/research/support/ b pca/prioritizing-pediatric-therapies.

The BPCA Priority List consists of key therapeutic needs in the medical treatment of children and adolescents identified for further study; it is organized by therapeutic area, which can be a group of conditions, a subgroup of the population, or a setting of care. The BPCA authorizing legislation requires the NIH to hold meetings with stakeholders for input into the prioritization process and to update the priority list every three years.

The most recent BPCA stakeholders meeting was held in Bethesda, Maryland on March 22, 2019. Please save the date for December 14–15, 2020 for the next stakeholders meeting. More information will be provided on the BPCA website as it becomes available. All inquiries should be submitted to Dr. Perdita Taylor-Zapata at the contact information above. This Notice serves as an update to the BPCA priority list of needs in pediatric therapeutics.

Priority List of Needs in Pediatric Therapeutics 2020–2021

In accordance with the BPCA legislation, the list outlines priority needs in pediatric therapeutics for multiple therapeutic areas listed below. The complete updated list of therapeutic areas and drugs that have been prioritized for study since the inception of the BPCA, and a summary of the NICHD’s plans and progress in all of these areas to date, can be found on the BPCA website at the following address: https://www.nichd.nih.gov/research/support/b pca/activities.

- Table 1: Infectious Disease Priorities
- Table 2: Cardiovascular Disease Priorities
- Table 3: Respiratory Disease Priorities
- Table 4: Intensive Care Priorities
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice is hereby given of a change in the meeting of the Epidemiology, Prevention and Behavior Research Review Subcommittee, June 8, 2020, 8:30 a.m. to June 8, 2020, 5:00 p.m., National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20892 which was published in the Federal Register on March 27, 2020, 85 FR 17336.

This notice is being amended to change the meeting location from the National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism; 6700B Rockledge Drive, Rooms A, B, C, Bethesda, MD 20892 to a telephone conference call. The meeting is closed to the public.


Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–09136 Filed 4–29–20; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Neuroscience Review Subcommittee, June 3, 2020, 8:30 a.m. to June 3, 2020, 5:00 p.m., National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Rooms A, B, C, Bethesda, MD 20892 which was published in the Federal Register on October 2, 2019, 84 FR 52518.

This notice is being amended to change the meeting location from the National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism; 6700B Rockledge Drive, Rooms A, B, C, Bethesda, MD 20892 to a telephone conference call. The meeting is closed to the public.


Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–09196 Filed 4–29–20; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Neuroscience Review Subcommittee, June 3, 2020, 8:30 a.m. to June 3, 2020, 5:00 p.m., National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Rooms A, B, C, Bethesda, MD 20892 which was published in the Federal Register on October 2, 2019, 84 FR 52518.

This notice is being amended to change the meeting location from the National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism; 6700B Rockledge Drive, Rooms A, B, C, Bethesda, MD 20892 to a telephone conference call. The meeting is closed to the public.


Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–09196 Filed 4–29–20; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6). Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Integrating Biospecimen Science Approaches into Clinical Assay Development.

Date: June 11, 2020.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute, Shady Grove, Medical Center Drive, Room 7W242, Rockville, MD 20850 (Telephone Conference Call).

Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W242, Bethesda, MD 20892, 240–276–6372, zhiquiang.zou@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–4: NCI Clinical and Translational R21 and Omnibus R03 Review.

[FR Doc. 2020–09136 Filed 4–29–20; 8:45 am]
BILLING CODE 4140–01–P